Date of Award
Doctor of Philosophy (Ph.D.)
Pharmaceutical and Chemical Sciences
Mamoun M. Alhamadsheh
First Committee Member
Miki S. Park
Second Committee Member
Third Committee Member
Fourth Committee Member
This project describes the development of a new antitumor therapeutic platform that combines the benefits of small-molecule drug conjugates (SMDCs) and antibody drug conjugates (ADCs). Valine-citrulline (VCit) dipeptide linkers are popular cathepsin B cleavable ADC linkers. Due to its instability in mouse serum, translating efficacy data from mouse to human is more difficult. It has been reported that replacing the VCit linker with glutamic acid-valine-citrulline (EVCit) improves ADC stability in mouse serum. The effect of the EVCit linker on the stability of SMDCs has not been reported so far. In a xenograft mouse model of prostate cancer, we found that incorporating the EVCit linker in PSMA-targeting SMDCs equipped with the transthyretin ligand AG10 resulted in conjugates with lower toxicity, extended half-life, and superior therapeutic efficacy compared to the standard metastatic castration-resistant prostate cancer (mCRPC) treatment option, docetaxel. This should improve the predictability of SMDC preclinical toxicity and efficacy data from mice.
Amin, Toufiq Ul. (2022). INCORPORATING GLUTAMIC ACID-VALINE-CITRULLINE LINKER IN TRIFUNCTIONAL MOLECULES TARGETING PSMA ENSURES ENHANCED STABILITY, SAFETY, AND EFFICACY IN MOUSE MODEL OF PROSTATE CANCER. University of the Pacific, Dissertation. https://scholarlycommons.pacific.edu/uop_etds/3837
In Copyright. URI: http://rightsstatements.org/vocab/InC/1.0/
This Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).